Hepatic localization of endothelin-1 in patients with idiopathic portal hypertension and cirrhosis of the liver

Patrick Sequeira Kamath, Herschel A. Carpenter, Ricardo V. Lloyd, Michael A. McKusick, Jeffery L. Steers, David M. Nagorney, Virginia M Miller

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Endothelin-1 (ET-1) may mediate increased resistance to hepatic sinusoidal blood flow. We evaluated the hepatic distribution of ET-1 in patients with idiopathic portal hypertension (IPH), in which liver architecture may be normal, and in patients with cirrhosis, in which distortion of hepatic sinusoidal architecture is prominent. Immunohistochemistry and in situ hybridization were used to localize ET-1 in hepatic tissue of patients with IPH and cirrhosis. ET-1 was measured in plasma from a peripheral vein, the hepatic vein, and the portal vein of patients with cirrhosis of the liver and controls. On immunohistochemistry and in situ hybridization, ET-1 was localized to periportal hepatocytes and sinusoidal cells in patients with IPH and cirrhosis. Minimal positive staining for ET-1 was observed in control livers. Plasma ET-1 levels were significantly greater in patients with cirrhosis than in controls. In patients with cirrhosis, ET-1 was greater in the hepatic vein compared with the portal vein. However, the level of plasma ET-1 in patients with cirrhosis did not correlate with either the presence of ascites or portacaval pressure gradient. We conclude that in IPH, ET-1 is localized to sites in which it can modulate intrahepatic resistance. In late stages of cirrhosis, ET-1 may not modulate resistance. We speculate that vascular resistance in late stages of cirrhosis probably results from distortion of hepatic architecture.

Original languageEnglish (US)
Pages (from-to)596-602
Number of pages7
JournalLiver Transplantation
Volume6
Issue number5
StatePublished - 2000

Fingerprint

Endothelin-1
Liver Cirrhosis
Fibrosis
Liver
Hepatic Veins
Portal Vein
In Situ Hybridization
Banti's syndrome
Immunohistochemistry
Ascites
Vascular Resistance
Hepatocytes
Veins
Staining and Labeling
Pressure

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

Kamath, P. S., Carpenter, H. A., Lloyd, R. V., McKusick, M. A., Steers, J. L., Nagorney, D. M., & Miller, V. M. (2000). Hepatic localization of endothelin-1 in patients with idiopathic portal hypertension and cirrhosis of the liver. Liver Transplantation, 6(5), 596-602.

Hepatic localization of endothelin-1 in patients with idiopathic portal hypertension and cirrhosis of the liver. / Kamath, Patrick Sequeira; Carpenter, Herschel A.; Lloyd, Ricardo V.; McKusick, Michael A.; Steers, Jeffery L.; Nagorney, David M.; Miller, Virginia M.

In: Liver Transplantation, Vol. 6, No. 5, 2000, p. 596-602.

Research output: Contribution to journalArticle

Kamath, PS, Carpenter, HA, Lloyd, RV, McKusick, MA, Steers, JL, Nagorney, DM & Miller, VM 2000, 'Hepatic localization of endothelin-1 in patients with idiopathic portal hypertension and cirrhosis of the liver', Liver Transplantation, vol. 6, no. 5, pp. 596-602.
Kamath, Patrick Sequeira ; Carpenter, Herschel A. ; Lloyd, Ricardo V. ; McKusick, Michael A. ; Steers, Jeffery L. ; Nagorney, David M. ; Miller, Virginia M. / Hepatic localization of endothelin-1 in patients with idiopathic portal hypertension and cirrhosis of the liver. In: Liver Transplantation. 2000 ; Vol. 6, No. 5. pp. 596-602.
@article{0f66f112ab0e4bb8900462ddff476e00,
title = "Hepatic localization of endothelin-1 in patients with idiopathic portal hypertension and cirrhosis of the liver",
abstract = "Endothelin-1 (ET-1) may mediate increased resistance to hepatic sinusoidal blood flow. We evaluated the hepatic distribution of ET-1 in patients with idiopathic portal hypertension (IPH), in which liver architecture may be normal, and in patients with cirrhosis, in which distortion of hepatic sinusoidal architecture is prominent. Immunohistochemistry and in situ hybridization were used to localize ET-1 in hepatic tissue of patients with IPH and cirrhosis. ET-1 was measured in plasma from a peripheral vein, the hepatic vein, and the portal vein of patients with cirrhosis of the liver and controls. On immunohistochemistry and in situ hybridization, ET-1 was localized to periportal hepatocytes and sinusoidal cells in patients with IPH and cirrhosis. Minimal positive staining for ET-1 was observed in control livers. Plasma ET-1 levels were significantly greater in patients with cirrhosis than in controls. In patients with cirrhosis, ET-1 was greater in the hepatic vein compared with the portal vein. However, the level of plasma ET-1 in patients with cirrhosis did not correlate with either the presence of ascites or portacaval pressure gradient. We conclude that in IPH, ET-1 is localized to sites in which it can modulate intrahepatic resistance. In late stages of cirrhosis, ET-1 may not modulate resistance. We speculate that vascular resistance in late stages of cirrhosis probably results from distortion of hepatic architecture.",
author = "Kamath, {Patrick Sequeira} and Carpenter, {Herschel A.} and Lloyd, {Ricardo V.} and McKusick, {Michael A.} and Steers, {Jeffery L.} and Nagorney, {David M.} and Miller, {Virginia M}",
year = "2000",
language = "English (US)",
volume = "6",
pages = "596--602",
journal = "Liver Transplantation",
issn = "1527-6465",
publisher = "John Wiley and Sons Ltd",
number = "5",

}

TY - JOUR

T1 - Hepatic localization of endothelin-1 in patients with idiopathic portal hypertension and cirrhosis of the liver

AU - Kamath, Patrick Sequeira

AU - Carpenter, Herschel A.

AU - Lloyd, Ricardo V.

AU - McKusick, Michael A.

AU - Steers, Jeffery L.

AU - Nagorney, David M.

AU - Miller, Virginia M

PY - 2000

Y1 - 2000

N2 - Endothelin-1 (ET-1) may mediate increased resistance to hepatic sinusoidal blood flow. We evaluated the hepatic distribution of ET-1 in patients with idiopathic portal hypertension (IPH), in which liver architecture may be normal, and in patients with cirrhosis, in which distortion of hepatic sinusoidal architecture is prominent. Immunohistochemistry and in situ hybridization were used to localize ET-1 in hepatic tissue of patients with IPH and cirrhosis. ET-1 was measured in plasma from a peripheral vein, the hepatic vein, and the portal vein of patients with cirrhosis of the liver and controls. On immunohistochemistry and in situ hybridization, ET-1 was localized to periportal hepatocytes and sinusoidal cells in patients with IPH and cirrhosis. Minimal positive staining for ET-1 was observed in control livers. Plasma ET-1 levels were significantly greater in patients with cirrhosis than in controls. In patients with cirrhosis, ET-1 was greater in the hepatic vein compared with the portal vein. However, the level of plasma ET-1 in patients with cirrhosis did not correlate with either the presence of ascites or portacaval pressure gradient. We conclude that in IPH, ET-1 is localized to sites in which it can modulate intrahepatic resistance. In late stages of cirrhosis, ET-1 may not modulate resistance. We speculate that vascular resistance in late stages of cirrhosis probably results from distortion of hepatic architecture.

AB - Endothelin-1 (ET-1) may mediate increased resistance to hepatic sinusoidal blood flow. We evaluated the hepatic distribution of ET-1 in patients with idiopathic portal hypertension (IPH), in which liver architecture may be normal, and in patients with cirrhosis, in which distortion of hepatic sinusoidal architecture is prominent. Immunohistochemistry and in situ hybridization were used to localize ET-1 in hepatic tissue of patients with IPH and cirrhosis. ET-1 was measured in plasma from a peripheral vein, the hepatic vein, and the portal vein of patients with cirrhosis of the liver and controls. On immunohistochemistry and in situ hybridization, ET-1 was localized to periportal hepatocytes and sinusoidal cells in patients with IPH and cirrhosis. Minimal positive staining for ET-1 was observed in control livers. Plasma ET-1 levels were significantly greater in patients with cirrhosis than in controls. In patients with cirrhosis, ET-1 was greater in the hepatic vein compared with the portal vein. However, the level of plasma ET-1 in patients with cirrhosis did not correlate with either the presence of ascites or portacaval pressure gradient. We conclude that in IPH, ET-1 is localized to sites in which it can modulate intrahepatic resistance. In late stages of cirrhosis, ET-1 may not modulate resistance. We speculate that vascular resistance in late stages of cirrhosis probably results from distortion of hepatic architecture.

UR - http://www.scopus.com/inward/record.url?scp=0033822103&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033822103&partnerID=8YFLogxK

M3 - Article

C2 - 10980059

AN - SCOPUS:0033822103

VL - 6

SP - 596

EP - 602

JO - Liver Transplantation

JF - Liver Transplantation

SN - 1527-6465

IS - 5

ER -